

FY2018 Regulatory Science Report: Long Acting Injectables and Implants

This section contains only new information from FY2018. For background scientific information and outcomes from previous years on this research topic, please refer to:

- FY2016 Regulatory Science Report: Long-Acting Injectable Formulations (<https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm549166.htm>)
- FYs 2013-2017 Regulatory Science Report: Long-Acting Injectables and Implants (<https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm597035.htm>)

Introduction


Our research on long acting injectables (LAI) and implants is targeted on providing a scientific foundation for the efficient development of generic competition in this product category. In FY18, there were 15 active research projects on long-acting injectables and implants including nine grants and five contracts as well as one internal collaboration. The focus of these projects are: 1) to explore biorelevant in vitro-in vivo correlations (IVIVCs) for biodegradable injectable poly lactide-co-glycolide (PLGA) microspheres; 2) to investigate dissolution methods for LAI drug products including PLGA microspheres and implants and multivesicular liposomes (MVLs); 3) to obtain a better understanding of the impact of properties of PLGA polymers on product performance; 4) to develop modeling tools to facilitate development of generic LAI formulation development as well as bioequivalence guidances for LAI formulations; 5) to investigate potential peptide PLGA interactions during product manufacturing and use; 6) to develop analytical method for separating PLGA polymers when used in mixture; and, 7) to develop methods for fully characterizing structure of branched PLGA polymers.

Research

All projects have made significant process. Here are some highlights:


- 1) An IVIVC has been established for naltrexone microspheres using a rabbit model (**Figure 1**). All in-house prepared formulations were compositionally equivalent with manufacturing differences. Vivitrol® was also evaluated in the study. The developed IVRT method was able to discriminate the formulations with differences in physicochemical properties.
- 2) Interactions between various solvents and PLGA polymers with similar molecular weight, but different L/G ratios were investigated. **Figure 2** shows PLGA solubility in various solvents at 30°C. The information on PLGA solubility in various solvents will be helpful for understanding effects of solvent on formulation development as well as polymer characterization.
- 3) A novel IVRT method for assessing in vitro drug release profile of MVLs using USP Apparatus II coupled with in-line continuous UV monitoring has been developed. A tri-phasic release characteristic was observed under all testing conditions, comprised of an initial burst release, lag phase, and a secondary release. Compared to conventional sample-and-separate method based on water shaker, this method could be a better tool to obtain mechanistic understanding of drug release from MVLs.

Figure 1. Graphical abstract “Development of In Vitro-In Vivo Correlation of Parenteral Naltrexone Loaded Polymeric Microspheres”.¹



A: Particle size of all tested formulations. B: In vitro release profiles of all tested formulations. C: Deconvoluted in vivo release profiles. D: IVIVC.

Figure 2. PLGA Solubility in Various Solvents at 30°C.



¹ <https://www.sciencedirect.com/science/article/pii/S0168365917305096?via%3Dihub#f0040>

Research Projects and Collaborations

New Grants and Contracts

- New Contract (HHSF223201810115C) *Impact of Polymer Source Variations on Parenteral Microsphere Drug Product Performance* with Diane J. Burgess at University of Connecticut, Department of Pharmaceutical Sciences
- New Contract (HHSF223201810187C) *Influence of Raw Materials, Manufacturing Variables, and Storage Conditions on In Vitro and In Vivo Performance of Exenatide in PLGA Microspheres* with Steven Schwendeman at the University of Michigan, College of Pharmacy

Continuing Grants and Contracts

- Active Grant (1U01FD004931) *In Vitro In Vivo Correlations of Parenteral Microsphere Drug Products* with Diane J. Burgess at University of Connecticut
- Active Grant (1U01FD005169) *Dissolution Methods for Parenteral Sustained Release Implant Drug Products* with Diane J. Burgess at University of Connecticut
- Active Contract (HHSF223201510102C) *Computational Drug Delivery: Leveraging Predictive Models to Develop Bioequivalent Generic Long Acting Injections* with Sam Rothstein at Qrono, Inc.
- Active Grant (1U01FD005442) *Pharmacometric Modeling and Simulation for Evaluation of Bioequivalence for Leuprolide Acetate Injection* with Catherine Mary, Turner Sherwin at University of Utah
- Active Grant (1U01FD005444) *Data-Fusion Based Platform Development of Population PKPD Modeling and Statistical Analysis for Bioequivalence Assessment of Long-Acting Injectable Products* with Seongkyu Yoon at University of Massachusetts
- Active Grant (1U01FD005463) *Development of PBPK Simulation for Long-Acting Injectable Microspheres* with Viera Lukacova at Simulations Plus
- Active Grant (1U01FD005446) *Development of a Dissolution Method for Long-Acting Periodontal Drug Products* with Kevin S. Li at University of Cincinnati
- Active Grant (1U01FD005447) *Biorelevant Dissolution Methods for Particulate Dosage Forms in the Periodontal Pocket* with Lisa C. Rohan at Magee-Women's Research Institute and Foundation
- Active Grant (1U01FD005443) *Development of Real-Time and Accelerated Dissolution Methods for a Long-Acting Levonorgestrel Intrauterine System* with Diane J. Burgess at University of Connecticut
- Active Contract (HHSF223201510170C) *Influence of Raw Materials, Manufacturing Variables, and Storage Conditions on Release Performance of Long Acting Release Microsphere Products* with Steven Schwendeman at University of Michigan
- Active Grant (1U01FD005847) *Investigation of Peptide-Polymer Interactions in PLGA Microspheres* with Steven Schwendeman at University of Michigan
- Active Contract (HHSF223201610091C) *Advanced Analytical Techniques for Mixed Polymer Drug-Delivery Systems* with Kinam Park at Akina, Inc.
- Active Contract (HHSF223201710123C) *Development of Analysis Technique for Structural Characterization of Star-Shaped Polyesters Used for Drug Delivery* with Kinam Park at Akina, Inc.
- Active Contract (HHSF223201710135C) *In-Vitro In-Vivo Correlation of the Long-Acting Injectable Suspensions Improve Scientific Approaches to Evaluate Generic Drugs* with Diane J. Burgess at University of Connecticut

Active FDA Lab Collaborations

- *Bupivacaine Multivesicle Liposomes* with CDRH

Outcomes

Product Specific Guidance

- *New Draft Guidance for Bupivacaine Injection Injectable, Liposomal*. FDA Guidance Posting. Feb. 8, 2018. [Link to Posting](#).
- *New Draft Guidance for Leuprolide Acetate; Norethindrone Acetate Intramuscular; Oral Injectable; Tablet*. FDA Guidance Posting. Feb. 8, 2018. [Link to Posting](#).

Publications

- Beekman, C., Matta, M., Thomas, C., Mohammad, A., Stewart, S., Xu, L., Chockalingam, A., Shea, K., Sun, D., Jiang, W., Patel, V., and Rouse, R. *Comparative Evaluation of US Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution After Intravenous Dosing in Rats*. *Nanomaterials*. (2018) **8**(1):10. doi: [10.3390/nano8010010](#). PMID: [29283393](#).
- Cheng, N., Rahman, M., Alatawi, Y., Qian, J., Peissig, P., Berg, R., Page, D., and Hansen, R. *Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs*. *Drug Safety*. (2018) **41**(4):363. doi: [10.1007/s40264-017-0624-0](#). PMID: [29196989](#).
- Garner, J., Skidmore, S., Park, H., Park, K., Choi, S., and Wang, Y. *Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations*. *J Pharm Sci*. (2018) **107**(1):353–361. doi: [10.1016/j.xphs.2017.10.027](#). PMID: [29107048](#).

Presentations

- Burgess, D. *In Vitro Drug Release from Complex Parenterals and Development of IVIVCs*. Presentation at Public Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. White Oak, MD, Oct. 6, 2017.
- Kinam, P. *Demonstrating Equivalence of Generic Complex Drug Substances and Formulations: Advances in Characterization and In Vitro Testing*. Presentation at Public Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. White Oak, MD, Oct. 6, 2017.
- Schwendeman, S. *Formulation Characterization of PLGA Microspheres*. Presentation at Public Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. White Oak, MD, Oct. 6, 2017.
- Sharan, S. *Evaluation of Residual Levonorgestrel As Potential Bioequivalence Metric for A Long Acting Intrauterine System Using Quantitative Modeling and Simulation Approach*. Presentation at American Association of Pharmaceutical Scientists Webinar. Webinar, MD, Oct. 12, 2017.
- Jiang, J. *An Overview of Challenges and Opportunities in the Development of Complex Generic Drug Products*. Presentation at DIA Webinar. Silver Spring, MD, Mar. 5, 2018.
- Manna, S. *Liposomes: Physicochemical Characterization and In Vitro Drug Release Testing*. Presentation at Complex Generic Drug Product Development Workshop. Silver Spring, MD, Sept. 12, 2018.
- Sharan, S. *Application of Modeling and Simulation in Establishing Appropriate Bioequivalence Limits*

for Complex Formulations. Presentation at Complex Generic Drug Product Development Workshop. Silver Spring, MD, Sept. 12, 2018.

- Qin, B. *Considerations for Establishing Q1/Q2 Sameness of Complex Formulations*. Presentation at Complex Generic Drug Product Development Workshop. Silver Spring, MD, Sept. 12, 2018.

Poster Presentations

- Andhariya, JV., Shen, J., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *Development of In Vitro-In Vivo Correlation of Parenteral Naltrexone Loaded Polymeric Microspheres*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Andhariya, JV., Shen, J., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *Effect of Manufacturing Processes on Critical Quality Attributes of Peptide Microspheres*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Andhariya, JV., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *Effect of Manufacturing Processes on Burst Release of Risperidone Microspheres*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Andhariya, JV., Shen, Y, Z., S, C., Y, W., and DJ, B. *Effect of Manufacturing Difference on the Drug Release Characteristics of Peptide Microspheres*. Poster Presentation at Controlled Release Society Annual Meeting. New York City, NY, July 22, 2018.
- Andhariya, JV., R, J., J, S., Y, Z., S, C., Y, W., and DJ, B. *Evaluation of Effect of Minor Manufacturing Changes and Establishment of IVIVC for Compositionally Equivalent Parenteral Microsphere Drug Products*. Poster Presentation at GPEN 2018. Singapore, Singapore, Sept. 26, 2018.
- Bao, Q., Gu, B., Price, C., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *In Vitro Release Testing of Long-Acting Levonorgestrel Intrauterine System*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Bao, Q., Gu, B., Price, C., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *In Vitro Release Testing of Long-Acting Levonorgestrel Intrauterine System*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Bao, Q., Zou, Y., Wang, Y., Kozak, D., Choi, S., and Burgess, D. *Accelerated Drug Release Method for Long-Acting Levonorgestrel Intrauterine Systems*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Beig, A., Hong, J., Feng, L., Chang, R., Zhou, J., Ackermann, R., and Schwendeman, S. *PLGA-Peptide Interactions Relevant for Octreotide Loaded PLGA Microspheres*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Garner, J., Skidmore, S., Hadar, J., Park, K., Park, H., Choi, S., and Wang, Y. *Assay of PLGA Types in Microparticle Depo Formulations*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Hadar, J., Garner, J., Skidmore, S., Park, K., Choi, S., and Wang, Y. *The Effect of Lactide:Glycolide Ratio On PLGA Solubility in Selective Solvents*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Hadar, J., Garner, J., Skidmore, S., Park, H., Park, K., Kozak, D., and Wang, Y. *Solvent-Dependent PLGA Solubility for Separation of Plgas with Different L:G Ratios*. Poster Presentation at Controlled Release Society Annual Meeting. New York City, NY, July 22, 2018.
- Hadar, J., Garner, J., Skidmore, S., Park, K., Park, H., Kozak, D., and Wang, Y. *Correlation Analysis of Refractive Index (Dn/Dc) for Plgas with Different Ratios of Lactide to Glycolide*, Poster Presentation at

Controlled Release Society Annual Meeting. New York City, NY, July 22, 2018.

- Manna, S., Petrochenko, P., Wu, Y., Dong, Y., Koo, B., Chen, L., Ren, K., Oktem, B., Choi, S., Xu, X., Kozak, D., Wang, Y., and Zheng, J. *Assessing In Vitro Drug Release from Multivesicular Liposome: Comparison of Reverse Dialysis and Rotary Shaking Methods*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Manna, S., Petrochenko, P., Wu, Y., Koo, B., Ren, K., Chen, L., Dong, Y., Xu, X., Choi, S., Kozak, D., Wang, Y., and Zheng, J. *Assessing In Vitro Drug Release from Multivesicular Liposome: Comparison of Reverse Dialysis and Rotary Shaking Methods*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Manna, S., Petrochenko, P., Wu, Y., Koo, B., Ren, K., Chen, L., Dong, Y., Xu, X., Choi, S., Kozak, D., Wang, Y., and Zheng, J. *Probing Mechanism of Drug Release from Multivesicular Liposomes*. Poster Presentation at Controlled Release Society Annual Meeting. New York City, NY, July 23, 2018.
- Manna, S., Petrochenko, P., Wu, Y., Dong, Y., Koo, B., Chen, L., Ren, K., Oktem, B., Choi, S., Xu, X., Kozak, D., Wang, Y., and Zheng, J. *Developing Physicochemical Characterization and In Vitro Release Test Methods to Probe Drug Release Mechanism From Multivesicular Liposomes*. Poster Presentation at Microscopy and Microanalysis Annual Meeting. Baltimore, MD, Aug. 6, 2018.
- Manna, S., Petrochenko, P., Wu, Y., Dong, Y., Koo, B., Chen, L., Ren, K., Oktem, B., Choi, S., Xu, X., Kozak, D., Wang, Y., and Zheng, J. *Mechanistic Understanding of In Vitro Drug Release of Bupivacaine From Multivesicular Liposomes*. Poster Presentation at AAPS Pharm- Sci 360. Washington, DC, Nov. 6, 2018.
- Patel, S., Greene, A., MacPherson, J., Basha, I., Desai, S., Zou, Y., Sfeir, C., Rothstein, S., Little, S., and Rohan, L. *Design, Fabrication, and Evaluation of a Small Volume Biorelevant Dissolution Apparatus for Extended-Release Periodontal Microparticles*. Poster Presentation at Controlled Release Society Annual Meeting. New York City, NY, July 18, 2018.
- Shahraz et al. *Development of In Vitro-in-Vivo Correlation for Long Acting Injectable Microsphere Formulations*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Prokash et al. *Data-Fusion Based Platform for Comparing Pharmacokinetics of Long-Acting Injectable Products*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Skidmore, S., Garner, J., Park, K., Park, H., Choi, S., and Wang, Y. *The Impact of In Vitro Test Methods on Drug Release from PLGA Microparticles*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Suh, M., Kastellorizios, M., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *Formulation and Microstructural in Situ Forming Implants: In Vitro and In Vivo*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Suh, M., Kastellorizios, M., Zou, Y., Wang, Y., Choi, S., and Burgess, D. *Effect of Polymer Characteristics on Formation of in Situ Forming Implants in Subcutaneous Tissue*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Zhou, J., Hirota, K., Ackermann, R., Walker, J., Wang, Y., Choi, S., Schwendeman, A., and Schwendeman, S. *Reverse Engineering of the 1-Month Lupron Depot and Development of Q1/Q2 Formulations*. Poster Presentation at FDA Workshop: Demonstrating Equivalence of Generic Complex Drug Substances and Formulations. Silver Spring, MD, Oct. 6, 2017.
- Zhou, J., Hirota, K., Feng, M., Doty, A., Olsen, K., Ackermann, R., Wang, Y., Choi, S., Schwendeman, A., and Schwendeman, S. *In Vitro In Vivo Correlation of Leuprolide Acetate-Loaded PLGA Microspheres*. Poster Presentation at AAPS Annual Meeting. San Diego, CA, Nov. 12, 2017.
- Zhou, J., Walker, J., Ackermann, R., Olsen, K., Hong, J., Wang, Y., Jiang, X., Schwendeman, A., and Schwendeman, S. *Development and Characterization of Composition-Equivalent Formulations to the*

One- Month Lupron Depot. Poster Presentation at Controlled Release Society Annual Meeting. New York City, NY, July 22, 2018.